Premium
ACTIVATION OF THE AhR/ARNT PATHWAY IS ASSOCIATED WITH OUTCOME OF DLBCL PATIENTS AFTER TREATED WITH RITUXIMAB
Author(s) -
Jin F.,
Yu X.,
Liu X.,
Liu Y.,
Ma H.,
Qu L.,
Dai Y.
Publication year - 2019
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.27_2631
Subject(s) - rituximab , aryl hydrocarbon receptor nuclear translocator , oncology , medicine , cancer research , immunohistochemistry , gene , biology , immunology , lymphoma , transcription factor , aryl hydrocarbon receptor , genetics